MRNA-LNP approaches that program tissues to produce therapeutic proteins for obesity, outlining advances in delivery strategies and therapeutic potential.
Key Takeaways
- MRNA-LNP platforms can enable in situ production of therapeutic proteins within target metabolic tissues
- Preclinical and formulation advances show adipose-accumulated mRNA delivery achieving anti-obesity effects in models
- Combinatorial lipid designs and co-delivery strategies are advancing systemic and tissue-targeted obesity therapeutics